trending Market Intelligence /marketintelligence/en/news-insights/trending/644nrkie2mx5gmrrfynhlg2 content esgSubNav
In This List

Xtant Medical names interim replacement for outgoing CEO

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Xtant Medical names interim replacement for outgoing CEO

Xtant Medical Holdings Inc. appointed Michael Mainelli as the interim replacement for outgoing CEO Carl O'Connell, who led the company through a restructuring.

Mainelli has been on the board of the Belgrade, Mont.-based company since February and was the CEO of Stanmore Implants Worldwide Ltd. when it was purchased by Stryker Corp. in 2016.

O'Connell had been Xtant Medical's CEO since October 2016.

The company plans to look for a permanent CEO.

Xtant Medical develops regenerative medicines and implants for deformities and degenerative diseases affecting the spine.